(RTTNews) - Tuesday, Kyowa Kirin (4151.T) said it entered into an exclusive distribution agreement with Knight Therapeutics (GUD.TO) for POTELIGEO (mogamulizumab) in select Latin American countries. Under the agreement, Knight will seek regulatory approvals and commercialize POTELIGEO for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL), in Argentina, Brazil, Colombia and Mexico. The agreement marks the first introduction of POTELIGEO by Kyowa Kirin in Latin America and expands access to the therapy for patients with CTCL. Mogamulizumab is a humanized monoclonal antibody targeting CC-chemokine receptor 4 (CCR4), a protein consistently expressed on cancerous cells in MF and SS.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。